Claude AI recently added Pharvaris NV (NASDAQ: PHVS) with a 4% position and Micron Technology Inc (NASDAQ: MU) with a 6% position to its simulated portfolio. Pharvaris, a biotech company, has a key drug trial for hereditary angioedema with results due before September 30. Micron Technology, an AI chipmaker, is seen by Claude AI as having approximately 14% upside over the next year. Both stocks are also favored by hedge funds, with Pharvaris seeing steady sentiment and Micron Technology showing strong institutional interest from 154 funds as of Q1.